Insight into Cardioprotective Effects and Mechanisms of Dexmedetomidine.

Li Z, Lin L, Wu H, et al. Global, Regional, and National Death, and Disability-Adjusted Life-Years (DALYs) for cardiovascular disease in 2017 and trends and risk analysis from 1990 to 2017 using the Global Burden of Disease Study and implications for prevention. Front Public Health. 2021;9:559751. https://doi.org/10.3389/fpubh.2021.559751 .

doi: 10.3389/fpubh.2021.559751 pubmed: 34778156 pmcid: 8589040

Afonso J, Reis F. Dexmedetomidine: current role in anesthesia and intensive care. Rev Bras Anestesiol. 2012;62(1):118–33. https://doi.org/10.1016/S0034-7094(12)70110-1 .

doi: 10.1016/S0034-7094(12)70110-1 pubmed: 22248773

Brock L. Dexmedetomidine in adult patients in cardiac surgery critical care: an evidence-based review. AACN Adv Crit Care. 2019;30(3):259–68. https://doi.org/10.4037/aacnacc2019888 .

doi: 10.4037/aacnacc2019888 pubmed: 31462522

Vandemoortele O, Hannivoort LN, Vanhoorebeeck F, Struys M, Vereecke HEM. General purpose pharmacokinetic-pharmacodynamic models for target-controlled infusion of anaesthetic drugs: a narrative review. J Clin Med. 2022;11(9). https://doi.org/10.3390/jcm11092487 .

Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913. https://doi.org/10.1007/s40262-017-0507-7 .

doi: 10.1007/s40262-017-0507-7 pubmed: 28105598 pmcid: 5511603

Romagnoli S, Amigoni A, Blangetti I et al. Light sedation with dexmedetomidine: a practical approach for the intensivist in different ICU patients. Minerva Anestesiol. 2018;84(6):731-46. https://doi.org/10.23736/S0375-9393.18.12350-9 .

Lin YY, He B, Chen J, Wang ZN. Can dexmedetomidine be a safe and efficacious sedative agent in post-cardiac surgery patients? a meta-analysis. Crit Care. 2012;16(5):R169-R. https://doi.org/10.1186/cc11646 .

Shokri H, Ali I. A randomized control trial comparing prophylactic dexmedetomidine versus clonidine on rates and duration of delirium in older adult patients undergoing coronary artery bypass grafting. J Clin Anesth. 2020;61:109622-. https://doi.org/10.1016/j.jclinane.2019.09.016 .

Zi J, Fan Yo, Dong CH et al. Anxiety administrated by dexmedetomidine to prevent new-onset of postoperative atrial fibrillation in patients undergoing off-Pump coronary artery bypass graft. Int Heart J. 2020: https://doi.org/10.1536/ihj.19-132 . https://doi.org/10.1536/ihj.19-132 .

Piao GY, Wu JR. Systematic assessment of dexmedetomidine as an anesthetic agent: a meta-analysis of randomized controlled trials. Arch Med Sci. 2014;10(1):19–24. https://doi.org/10.5114/aoms.2014.40730 .

doi: 10.5114/aoms.2014.40730 pubmed: 24701209 pmcid: 3953974

Habibi V, Kiabi FH, Sharifi H. The effect of dexmedetomidine on the acute pain after cardiothoracic surgeries: a systematic review. Braz J Cardiovasc Surg. 2018;33(4):404-17. https://doi.org/10.21470/1678-9741-2017-0253 .

Penttilä J, Helminen A, Anttila M, Hinkka S, Scheinin H. Cardiovascular and parasympathetic effects of dexmedetomidine in healthy subjects. Can J Physiol Pharmacol. 2004;82(5):359–62. https://doi.org/10.1139/y04-028 .

doi: 10.1139/y04-028 pubmed: 15213737

Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93(2):382-94. 10.1097 / 00000542-200008000-00016.

Kang D, Lim C, Shim DJ, et al. The correlation of heart rate between natural sleep and dexmedetomidine sedation. Korean J Anesthesiol. 2019;72(2):164–8. https://doi.org/10.4097/kja.d.18.00208 .

doi: 10.4097/kja.d.18.00208 pubmed: 30481949

Yu GF, Jin SY, Chen JH, Yao WF, Song XR. The effects of novel α(2)-adrenoreceptor agonist dexmedetomidine on shivering in patients underwent caesarean section. Biosci Rep. 2019;39(2):BSR20181847. 10.1042/BSR20181847.

Geng ZY, Liu YF, Wang SS, Wang DX. Intra-operative dexmedetomidine reduces early postoperative nausea but not vomiting in adult patients after gynaecological laparoscopic surgery: a randomised controlled trial. Eur J Anaesthesiol. 2016;33(10):761–6. https://doi.org/10.1097/EJA.0000000000000491 .

doi: 10.1097/EJA.0000000000000491 pubmed: 27307217

Mahboobi SK. Dexmedetomidine and renal protection after cardiac surgery. J Clin Anesth. 2017;40:121–2. https://doi.org/10.1016/j.jclinane.2017.05.002 .

doi: 10.1016/j.jclinane.2017.05.002 pubmed: 28625433

Lin N, Vutskits L, Bebawy JF, Gelb AW. Perspectives on dexmedetomidine use for neurosurgical patients. J Neurosurg Anesthesiol. 2019;31(4):366–77. https://doi.org/10.1097/ANA.0000000000000554 .

doi: 10.1097/ANA.0000000000000554 pubmed: 30363004

Wong A, Smithburger PL, Kane-Gill SL. Review of adjunctive dexmedetomidine in the management of severe acute alcohol withdrawal syndrome. Am J Drug Alcohol Abuse. 2015;41(5):382–91. https://doi.org/10.3109/00952990.2015.1058390 .

doi: 10.3109/00952990.2015.1058390 pubmed: 26337198

Vega L, Sanchez-de-Toledo J, Gran F, et al. Prevention of opioid withdrawal syndrome after pediatric heart transplantation: usefulness of dexmedetomidine. Rev Esp Cardiol (Engl Ed). 2013;66(7):593–5. https://doi.org/10.1016/j.rec.2013.01.014 .

doi: 10.1016/j.rec.2013.01.014 pubmed: 24776215

Snapir A, Posti J, Kentala E et al. Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. Anesthesiology. 2006;105(5):902-10; quiz 1069-70. https://doi.org/10.1097/00000542-200611000-00010 .

Bao N, Tang B. Organ-protective effects and the underlying mechanism of dexmedetomidine. Mediators Inflamm. 2020;2020:6136105. https://doi.org/10.1155/2020/6136105 .

doi: 10.1155/2020/6136105 pubmed: 32454792 pmcid: 7232715

Yuki K. The immunomodulatory mechanism of dexmedetomidine. International immunopharmacology. 2021;97: 107709. https://doi.org/10.1016/j.intimp.2021.107709 .

doi: 10.1016/j.intimp.2021.107709 pubmed: 33933842 pmcid: 8324520

Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell research. 2019;29(5):347–64. https://doi.org/10.1038/s41422-019-0164-5 .

doi: 10.1038/s41422-019-0164-5 pubmed: 30948788 pmcid: 6796845

He Y, Yang ZY, Li JL, Li EY. Dexmedetomidine reduces the inflammation and apoptosis of doxorubicin-induced myocardial cells. Exp Mol Pathol. 2020;113:104371-. https://doi.org/10.1016/j.yexmp.2020.104371 .

Chen S, Li A, Wu J, et al. Dexmedetomidine reduces myocardial ischemia-reperfusion injury in young mice through MIF/AMPK/GLUT4 axis. BMC Anesthesiol. 2022;22(1):289. https://doi.org/10.1186/s12871-022-01825-z .

doi: 10.1186/s12871-022-01825-z pubmed: 36104681 pmcid: 9472426

Yuan M, Meng XW, Ma J et al. Dexmedetomidine protects H9c2 cardiomyocytes against oxygen-glucose deprivation/reoxygenation-induced intracellular calcium overload and apoptosis through regulating FKBP12.6/RyR2 signaling. Drug Des Devel Ther. 2019;13:3137-49. https://doi.org/10.2147/dddt.S219533 .

Yang FY, Zhang L, Zheng Y, Dong H. Dexmedetomidine attenuates ischemia and reperfusion-induced cardiomyocyte injury through p53 and forkhead box O3a (FOXO3a)/p53-upregulated modulator of apoptosis (PUMA) signaling signaling. Bioengineered. 2022;13(1):1377–87. https://doi.org/10.1080/21655979.2021.2017611 .

doi: 10.1080/21655979.2021.2017611 pubmed: 34974801 pmcid: 8805856

Peng K, Chen WR, Xia F, et al. Dexmedetomidine post-treatment attenuates cardiac ischaemia/reperfusion injury by inhibiting apoptosis through HIF-1α signalling. J Cell Mol Med. 2020;24(1):850–61. https://doi.org/10.1111/jcmm.14795 .

doi: 10.1111/jcmm.14795 pubmed: 31680420

Sun T, Gong Q, Wu Y, et al. Dexmedetomidine alleviates cardiomyocyte apoptosis and cardiac dysfunction may be associated with inhibition of RhoA/ROCK pathway in mice with myocardial infarction. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(7):1569–77. https://doi.org/10.1007/s00210-021-02082-6 .

doi: 10.1007/s00210-021-02082-6 pubmed: 33782744

Zhang C, Li XY, Luo ZZ, Wu TW, Hu H. Upregulation of LINC00982 inhibits cell proliferation and promotes cell apoptosis by regulating the activity of PI3K/AKT signaling pathway in renal cancer. Eur Rev Med Pharmacol Sci. 2019;23(4):1443-50. https://doi.org/10.26355/eurrev_201902_17101 .

Wang T, Li Z, Xia S, et al. Dexmedetomidine promotes cell proliferation and inhibits cell apoptosis by regulating LINC00982 and activating the phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT) signaling in hypoxia/reoxygenation-induced H9c2 cells. Bioengineered. 2022;13(4):10159–67. https://doi.org/10.1080/21655979.2022.2060900 .

doi: 10.1080/21655979.2022.2060900 pubmed: 35466860 pmcid: 9161950

Chang JH, Jin MM, Liu JT. Dexmedetomidine pretreatment protects the heart against apoptosis in ischemia/reperfusion injury in diabetic rats by activating PI3K/Akt signaling in vivo and in vitro. Biomed Pharmacother. 2020;127:110188. https://doi.org/10.1016/j.biopha.2020.110188 .

doi: 10.1016/j.biopha.2020.110188 pubmed: 32407987

Yu P, Zhang J, Ding Y, et al. Dexmedetomidine post-conditioning alleviates myocardial ischemia-reperfusion injury in rats by ferroptosis inhibition via SLC7A11/GPX4 axis activation. Hum Cell. 2022;35(3):836–48. https://doi.org/10.1007/s13577-022-00682-9 .

doi: 10.1007/s13577-022-00682-9 pubmed: 35212945

Wang C, Yuan W, Hu A, et al. Dexmedetomidine alleviated sepsis-induced myocardial ferroptosis and septic heart injury. Mol Med Rep. 2020;22(1):175–84. https://doi.org/10.3892/mmr.2020.11114 .

doi: 10.3892/mmr.2020.11114 pubmed: 32377745 pmcid: 7248514

Wang Z, Yao M, Jiang L, et al. Dexmedetomidine attenuates myocardial ischemia/reperfusion-induced ferroptosis via AMPK/GSK-3β/Nrf2 axis. Biomed Pharmacother. 2022;154: 113572. https://doi.org/10.1016/j.biopha.2022.113572 .

doi: 10.1016/j.biopha.2022.113572 pubmed: 35988428

Li F, Hu Z, Huang Y, Zhan H. Dexmedetomidine ameliorates diabetic cardiomyopathy by inhibiting ferroptosis through the Nrf2/GPX4 pathway. Journal of cardiothoracic surgery. 2023;18(1):223. https://doi.org/10.1186/s13019-023-02300-7 .

doi: 10.1186/s13019-023-02300-7 pubmed: 37430319 pmcid: 10334540

Ma X, Xu J, Gao N, Tian J, Song T. Dexmedetomidine attenuates myocardial ischemia-reperfusion injury via inhibiting ferroptosis by the cAMP/PKA/CREB pathway. Mol Cell Probes. 2023;68: 101899. https://doi.org/10.1016/j.mcp.2023.101899 .

doi: 10.1016/j.mcp.2023.101899 pubmed: 36775106

Chen X, Tian PC, Wang K, Wang M, Wang K. Pyroptosis: role and mechanisms in cardiovascular disease. Front Cardiovasc Med. 2022;9: 897815. https://doi.org/10.3389/fcvm.2022.897815 .

doi: 10.3389/fcvm.2022.897815 pubmed: 35647057 pmcid: 9130572

Zhong Y, Li YP, Yin YQ, Hu BL, Gao H. Dexmedetomidine inhibits pyroptosis by down-regulating miR-29b in myocardial ischemia reperfusion injury in rats. Int Immunopharmacol. 2020;86: 106768. https://doi.org/10.1016/j.intimp.2020.106768 .

doi: 10.1016/j.intimp.2020.106768 pubmed: 32679539

Huang Y, Sun X, Juan Z, et al. Dexmedetomidine attenuates myocardial ischemia-reperfusion injury in vitro by inhibiting NLRP3 Inflammasome activation. BMC Anesthesiol. 2021;21(1):104. https://doi.org/10.1186/s12871-021-01334-5 .

doi: 10.1186/s12871-021-01334-5 pubmed: 33823789 pmcid: 8022424

Takahashi M. Cell-specific roles of NLRP3 inflammasome in myocardial infarction. J Cardiovasc Pharmacol. 2019;74(3):188–93. https://doi.org/10.1097/fjc.0000000000000709 .

doi: 10.1097/fjc.0000000000000709 pubmed: 31356542

Wang L, Liu J, Wang Z, et al. Dexmedetomidine abates myocardial ischemia reperfusion injury through inhibition of pyroptosis via regulation of miR-665/MEF2D/Nrf2 axis. Biomed Pharmacother. 2023;165: 115255. https://doi.org/10.1016/j.biopha.2023.115255 .

doi: 10.1016/j.biopha.2023.115255 pubmed: 37549462

Yin W, Wang C, Peng Y, et al. Dexmedetomidine alleviates H(2)O(2)-induced oxidative stress and cell necroptosis through activating of α2-adrenoceptor in H9C2 cells. Mol Biol Rep. 2020;47(5):3629–39. https://doi.org/10.1007/s11033-020-05456-w .

doi: 10.1007/s11033-020-05456-w pubmed: 32342432

Chen JY, Jiang ZZ, Zhou X, et al. Dexmedetomidine preconditioning protects cardiomyocytes against hypoxia/reoxygenation-induced necroptosis by inhibiting HMGB1-mediated inflammation. Cardiovasc Drugs Ther. 2019;33(1):45–54. https://doi.org/10.1007/s10557-019-06857-1 .

doi: 10.1007/s10557-019-06857-1 pubmed: 30675709

Shen R, Pan D, Wang Z, et al. The effects of dexmedetomidine post-conditioning on cardiac and neurological outcomes after cardiac arrest and resuscitation in swine. Shock. 2021;55(3):388–95. https://doi.org/10.1097/shk.0000000000001637 .

doi: 10.1097/shk.0000000000001637 pubmed: 32925602

Shao Q, Xia J, Wu P, Ying J. Dexmedetomidine protects cardiac microvascular endothelial cells from the damage of ogd/r through regulation of the pparδ-mediated autophagy. Microcirculation . 2021;28(4):e12675. https://doi.org/10.1111/micc.12675 .

Denton D, Kumar S. Autophagy-dependent cell death. Cell death and differentiation. 2019;26(4):605–16. https://doi.org/10.1038/s41418-018-0252-y .

doi: 10.1038/s41418-018-0252-y pubmed: 30568239

Zhao S, Wu W, Lin X, et al. Protective effects of dexmedetomidine in vital organ injury: crucial roles of autophagy. Cell Mol Biol Lett. 2022;27(1):34. https://doi.org/10.1186/s11658-022-00335-7 .

doi: 10.1186/s11658-022-00335-7 pubmed: 35508984 pmcid: 9066865

Xiao Y, Li J, Qiu L, et al. Dexmedetomidine protects human cardiomyocytes against ischemia-reperfusion injury through α2-adrenergic receptor/AMPK-dependent autophagy. Front Pharmacol. 2021;12: 615424. https://doi.org/10.3389/fphar.2021.615424 .

doi: 10.3389/fphar.2021.615424 pubmed: 34093174 pmcid: 8176440

Singhal AK, Symons JD, Boudina S, Jaishy B, Shiu YT. Role of Endothelial Cells in Myocardial Ischemia-Reperfusion Injury. Vascular disease prevention. 2010;7:1-14. 0.2174/1874120701007010001.

Yu TY, Liu D, Gao M et al. Dexmedetomidine prevents septic myocardial dysfunction in rats via activation of α7nAChR and PI3K/Akt- mediated autophagy. Biomed Pharmacother. 2019;120:109231-. https://doi.org/10.1016/j.biopha.2019.109231 .

Oh JE, Jun JH, Hwang HJ, et al. Dexmedetomidine restores autophagy and cardiac dysfunction in rats with streptozotocin-induced diabetes mellitus. Acta Diabetol. 2019;56(1):105–14. https://doi.org/10.1007/s00592-018-1225-9 .

doi: 10.1007/s00592-018-1225-9 pubmed: 30206697

Li Y, Qu M, Xing F, et al. The protective mechanism of dexmedetomidine in regulating Atg14L-Beclin1-Vps34 complex against myocardial ischemia-reperfusion injury. J Cardiovasc Trans Res. 2021;14(6):1063–74. https://doi.org/10.1007/s12265-021-10125-9 .

doi: 10.1007/s12265-021-10125-9

Rotter Sopasakis V, Sandstedt J, Johansson M, et al. Toll-like receptor-mediated inflammation markers are strongly induced in heart tissue in patients with cardiac disease under both ischemic and non-ischemic conditions. Int J Cardiol. 2019;293:238–47. https://doi.org/10.1016/j.ijcard.2019.06.033 .

doi: 10.1016/j.ijcard.2019.06.033 pubmed: 31230935

Gao JM, Meng XW, Zhang J et al. Dexmedetomidine protects cardiomyocytes against hypoxia/reoxygenation injury by suppressing TLR4-MyD88-NF-κB signaling. Biomed Res Int. 2017;2017:1674613-. https://doi.org/10.1155/2017/1674613 .

Yang YF, Peng K, Liu H, et al. Dexmedetomidine preconditioning for myocardial protection in ischaemia-reperfusion injury in rats by downregulation of the high mobility group box 1-toll-like receptor 4-nuclear factor κB signalling pathway. Clin Exp Pharmacol Physiol. 2017;44(3):353–61. https://doi.org/10.1111/1440-1681.12711 .

doi: 10.1111/1440-1681.12711 pubmed: 27998004

Zhang JJ, Peng K, Zhang J, Meng XW, Ji FH. Dexmedetomidine preconditioning may attenuate myocardial ischemia/reperfusion injury by down-regulating the HMGB1-TLR4-MyD88-NF-кB signaling pathway. PLoS One. 2017;12(2): e0172006. https://doi.org/10.1371/journal.pone.0172006 .

doi: 10.1371/journal.pone.0172006 pubmed: 28222157 pmcid: 5319750

Yuan T, Yang Z, Xian S, et al. Dexmedetomidine-mediated regulation of miR-17-3p in H9C2 cells after hypoxia/reoxygenation injury. Exp Ther Med. 2020;20(2):917–25. https://doi.org/10.3892/etm.2020.8775 .

doi: 10.3892/etm.2020.8775 pubmed: 32742334 pmcid: 7388268

Zhang J, Xia F, Zhao HF et al. Dexmedetomidine-induced cardioprotection is mediated by inhibition of high mobility group box-1 and the cholinergic anti-inflammatory pathway in myocardial ischemia-reperfusion injury. PLoS One. 2019;14(7):e0218726-e. https://doi.org/10.1371/journal.pone.0218726 .

Kong W, Kang K, Gao Y, et al. Dexmedetomidine alleviates LPS-induced septic cardiomyopathy via the cholinergic anti-inflammatory pathway in mice. Am J Transl Res. 2017;9(11):5040–7.

pubmed: 29218102 pmcid: 5714788

Xiong W, Zhou R, Qu Y, et al. Dexmedetomidine preconditioning mitigates myocardial ischemia/reperfusion injury via inhibition of mast cell degranulation. Biomed Pharmacother. 2021;141: 111853. https://doi.org/10.1016/j.biopha.2021.111853 .

doi: 10.1016/j.biopha.2021.111853 pubmed: 34237593

Zhang B, Zhang J, Ainiwaer Y, et al. Dexmedetomidine attenuates myocardial injury induced by renal ischemia/reperfusion by inhibiting the HMGB1-TLR4-MyD88-NF-κB signaling pathway. Ann Clin Lab Sci. 2021;51(3):376–84.

pubmed: 34162568

Zheng X, Li J, Fan Q, Zhao X, Chen K. Dexmedetomidine alleviates myocardial ischemia/reperfusion-induced injury and Ca(2+) overload via the microRNA-346-3p/CaMKIId axis. Int J Cardiol. 2021;338:185–95. https://doi.org/10.1016/j.ijcard.2021.03.016 .

doi: 10.1016/j.ijcard.2021.03.016 pubmed: 33731281

Pang Q, You L, Meng X, et al. Regulation of the JAK/STAT signaling pathway: the promising targets for cardiovascular disease. Biochem Pharmacol. 2023;213: 115587. https://doi.org/10.1016/j.bcp.2023.115587 .

doi: 10.1016/j.bcp.2023.115587 pubmed: 37187275

Chen ZR, Hong Y, Wen SH, Zhan YQ, Huang WQ. Dexmedetomidine pretreatment protects against myocardial ischemia/reperfusion injury by activating STAT3 signaling. Anesth Analg. 2023. https://doi.org/10.1213/ane.0000000000006487 .

doi: 10.1213/ane.0000000000006487 pubmed: 38100810 pmcid: 10629609

Pan S, Chen Y, Zhang X, Xie Y. The JAK2/STAT3 pathway is involved in dexmedetomidine-induced myocardial protection in rats undergoing cardiopulmonary bypass. Ann Transl Med. 2020;8(7):483. https://doi.org/10.21037/atm.2020.03.67 .

Kurdi M, Booz GW. Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of interleukin-6-type cytokine signaling. J Cardiovasc Pharmacol. 2007;50(2):126–41. https://doi.org/10.1097/FJC.0b013e318068dd49 .

doi: 10.1097/FJC.0b013e318068dd49 pubmed: 17703129

Comità S, Femmino S, Thairi C, et al. Regulation of STAT3 and its role in cardioprotection by conditioning: focus on non-genomic roles targeting mitochondrial function. Basic research in cardiology. 2021;116(1):56. https://doi.org/10.1007/s00395-021-00898-0 .

doi: 10.1007/s00395-021-00898-0 pubmed: 34642818 pmcid: 8510947

Shi X, Liu Z, Li J. Protective effects of dexmedetomidine on hypoxia/reoxygenation injury in cardiomyocytes by regulating the CHOP signaling pathway. Mol Med Rep. 2020;22(4):3307–15. https://doi.org/10.3892/mmr.2020.11442 .

doi: 10.3892/mmr.2020.11442 pubmed: 32945482 pmcid: 7453597

Chen WL, Jin N, Lin YY, et al. Immunomodulatory effects of fentanyl or dexmedetomidine hydrochloride infusion after allogeneic heart transplantation in mice. Reg Anesth Pain Med. 2018;43(5):509–15. https://doi.org/10.1097/AAP.0000000000000747 .

doi: 10.1097/AAP.0000000000000747 pubmed: 29509567

Ma Y, Yu XY, Wang Y. Dose-related effects of dexmedetomidine on immunomodulation and mortality to septic shock in rats. World J Emerg Med. 2018;9(1):56–63. https://doi.org/10.5847/wjem.j.1920-8642.2018.01.009 .

doi: 10.5847/wjem.j.1920-8642.2018.01.009 pubmed: 29290897 pmcid: 5717378

Dardalas I, Stamoula E, Rigopoulos P et al. Dexmedetomidine effects in different experimental sepsis in vivo models. Eur J Pharmacol. 2019;856:172401-. https://doi.org/10.1016/j.ejphar.2019.05.030 .

Sharma A, Tate M, Mathew G, et al. Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. Front Physiol. 2018;9:114. https://doi.org/10.3389/fphys.2018.00114 .

doi: 10.3389/fphys.2018.00114 pubmed: 29515457 pmcid: 5826188

Wang YG, Liu CZ, Li YZ, Peng Y, Yan SL. Cotreatments with Dex and Na(2)SeO(3) further improved antioxidant and anti-inflammatory protection of myocardial cells from I/R injury compared to their individual treatments. Free Radic Res. 2020;54(1):76–90. https://doi.org/10.1080/10715762.2019.1707198 .

doi: 10.1080/10715762.2019.1707198 pubmed: 31909644

Wu ZL, Davis JRJ, Zhu Y. Dexmedetomidine protects against myocardial ischemia/reperfusion injury by ameliorating oxidative stress and cell apoptosis through the Trx1-dependent Akt pathway. Biomed Res Int. 2020;2020:8979270. https://doi.org/10.1155/2020/8979270 .

doi: 10.1155/2020/8979270 pubmed: 33299886 pmcid: 7710428

Zhang J, Jiang H, Liu DH, Wang GN. Effects of dexmedetomidine on myocardial ischemia-reperfusion injury through PI3K-Akt-mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(15):6736-43. https://doi.org/10.26355/eurrev_201908_18565 .

Cheng XY, Hu J, Wang Y, et al. Effects of dexmedetomidine postconditioning on myocardial ischemia/reperfusion injury in diabetic rats: role of the PI3K/Akt-dependent signaling pathway. J Diabetes Res. 2018;2018:3071959-. https://doi.org/10.1155/2018/3071959 .

Hu B, Tian T, Li XT, et al. Dexmedetomidine postconditioning attenuates myocardial ischemia/reperfusion injury by activating the Nrf2/Sirt3/SOD2 signaling pathway in the rats. Redox Rep. 2023;28(1):2158526. https://doi.org/10.1080/13510002.2022.2158526 .

doi: 10.1080/13510002.2022.2158526 pubmed: 36738240 pmcid: 9904316

Li HX, Wang TH, Wu LX, et al. Role of Keap1-Nrf2/ARE signal transduction pathway in protection of dexmedetomidine preconditioning against myocardial ischemia/reperfusion injury. 2022. Biosci Rep. https://doi.org/10.1042/bsr20221306 .

Wu W, Du Z, Wu L. Dexmedetomidine attenuates hypoxia-induced cardiomyocyte injury by promoting telomere/telomerase activity: Possible involvement of ERK1/2-Nrf2 signaling pathway. Cell Biol Int. 2022;46(7):1036–46. https://doi.org/10.1002/cbin.11799 .

doi: 10.1002/cbin.11799 pubmed: 35312207

Borger M, von Haefen C, Bührer C, Endesfelder S. Cardioprotective Effects of Dexmedetomidine in an Oxidative-Stress In Vitro Model of Neonatal Rat Cardiomyocytes. Antioxidants (Basel, Switzerland). 2023;12(6). https://doi.org/10.3390/antiox12061206 .

Gao W, Du L, Li N, et al. Dexmedetomidine attenuates myocardial ischemia-reperfusion injury in hyperlipidemic rats by inhibiting inflammation, oxidative stress and NF-κB. Chemical biology & drug design. 2023;102(5):1176–85. https://doi.org/10.1111/cbdd.14324 .

doi: 10.1111/cbdd.14324

Zhu Z, Ling X, Zhou H, Zhang C. Dexmedetomidine at a dose of 1 µM attenuates H9c2 cardiomyocyte injury under 3 h of hypoxia exposure and 3 h of reoxygenation through the inhibition of endoplasmic reticulum stress. Exp Ther Med. 2021;21(2):132. https://doi.org/10.3892/etm.2020.9564 .

doi: 10.3892/etm.2020.9564 pubmed: 33376514

Liu XR, Li T, Cao L, et al. Dexmedetomidine attenuates H2O2-induced neonatal rat cardiomyocytes apoptosis through mitochondria- and ER-medicated oxidative stress pathways. Mol Med Rep. 2018;17(5):7258–64. https://doi.org/10.3892/mmr.2018.8751 .

doi: 10.3892/mmr.2018.8751 pubmed: 29568958 pmcid: 5928682

Yang YF, Wang H, Song N, et al. Dexmedetomidine attenuates ischemia/reperfusion-induced myocardial inflammation and apoptosis through inhibiting endoplasmic reticulum stress signaling. J Inflam Res. 2021;14:1217–33. https://doi.org/10.2147/jir.S292263 .

doi: 10.2147/jir.S292263

Zhang Y, Zhao Q, Li X, Ji F. Dexmedetomidine reversed hypoxia/reoxygenation injury-induced oxidative stress and endoplasmic reticulum stress-dependent apoptosis of cardiomyocytes via SIRT1/CHOP signaling pathway. Mol Cell Biochem. 2021;476(7):2803–12. https://doi.org/10.1007/s11010-021-04102-8 .

doi: 10.1007/s11010-021-04102-8 pubmed: 33725228

Wang L, Wang S, Jia T, et al. Dexmedetomidine prevents cardiomyocytes from hypoxia/reoxygenation injury via modulating tetmethylcytosine dioxygenase 1-mediated DNA demethylation of Sirtuin1. Bioengineered. 2022;13(4):9369–86. https://doi.org/10.1080/21655979.2022.2054762 .

doi: 10.1080/21655979.2022.2054762 pubmed: 35387565 pmcid: 9161963

Zhu Z, Ling X, Zhou H, Zhang C, Yan W. Dexmedetomidine attenuates cellular injury and apoptosis in H9c2 cardiomyocytes by regulating p-38MAPK and endoplasmic reticulum stress. Drug Des Devel Ther. 2020;14:4231–43. https://doi.org/10.2147/dddt.S265970 .

doi: 10.2147/dddt.S265970 pubmed: 33116411 pmcid: 7568428

Chu Y, Teng J, Feng P, et al. Dexmedetomidine attenuates hypoxia/reoxygenation injury of H9C2 myocardial cells by upregulating miR-146a expression via the MAPK signal pathway. Pharmacology. 2022;107(1–2):14–27. https://doi.org/10.1159/000506814 .

doi: 10.1159/000506814 pubmed: 34718238

Mitra A, Ray A, Datta R, Sengupta S, Sarkar S. Cardioprotective role of P38 MAPK during myocardial infarction via parallel activation of α-crystallin B and Nrf2. J Cell Physiol. 2014;229(9):1272–82. https://doi.org/10.1002/jcp.24565 .

doi: 10.1002/jcp.24565 pubmed: 24464634

Zou H, Liu G. Inhibition of endoplasmic reticulum stress through activation of MAPK/ERK signaling pathway attenuates hypoxia-mediated cardiomyocyte damage. J Recep Signal Transduct Res. 2021;41(6):532–7. https://doi.org/10.1080/10799893.2020.1831534 .

doi: 10.1080/10799893.2020.1831534

Saurin AT, Martin JL, Heads RJ, et al. The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes. FASEB J. 2000;14(14):2237–46. https://doi.org/10.1096/fj.99-0671com .

doi: 10.1096/fj.99-0671com pubmed: 11053245

Li JJ, Zhao Y, Zhou N, Li LY, Li K. Dexmedetomidine attenuates myocardial ischemia-reperfusion injury in diabetes mellitus by inhibiting endoplasmic reticulum stress. J Diabetes Res. 2019;2019:7869318-. https://doi.org/10.1155/2019/7869318 .

Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821–32. https://doi.org/10.1016/j.cell.2010.01.040 .

doi: 10.1016/j.cell.2010.01.040 pubmed: 20303873

Ong G, Logue SE. Unfolding the Interactions between Endoplasmic Reticulum Stress and Oxidative Stress. Antioxidants (Basel, Switzerland). 2023;12(5). https://doi.org/10.3390/antiox12050981 .

Weng XJ, Zhang XD, Lu XF, Wu J, Li ST. Reduced mitochondrial response sensitivity is involved in the anti-apoptotic effect of dexmedetomidine pretreatment in cardiomyocytes. Int J Mol Med. 2018;41(4):2328–38. https://doi.org/10.3892/ijmm.2018.3384 .

doi: 10.3892/ijmm.2018.3384 pubmed: 29328437

Yu JL, Jin Y, Cao XY, Gu HH. Dexmedetomidine alleviates doxorubicin cardiotoxicity by inhibiting mitochondrial reactive oxygen species generation. Hum Cell. 2020;33(1):47–56. https://doi.org/10.1007/s13577-019-00282-0 .

doi: 10.1007/s13577-019-00282-0 pubmed: 31643023

Deng X, Ye F, Zeng L, et al. Dexmedetomidine Mitigates myocardial ischemia/reperfusion-induced mitochondrial apoptosis through targeting lncRNA HCP5. Am J Chin Med. 2022;50(6):1529–51. https://doi.org/10.1142/s0192415x22500641 .

doi: 10.1142/s0192415x22500641 pubmed: 35931662

Kulek AR, Anzell A, Wider JM, Sanderson TH, Przyklenk K. Mitochondrial quality control: role in cardiac models of lethal ischemia-reperfusion injury. Cells. 2020;9(1). https://doi.org/10.3390/cells9010214 .

Jiang CC, Xia ML, Wang M, Chen SP. Dexmedetomidine preconditioning protects isolated rat hearts against ischemia/reperfusion injuries and its mechanism. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013;42(3):326–30.

pubmed: 23801622

Behmenburg F, Pickert E, Mathes A, et al. The Cardioprotective Effect of Dexmedetomidine in Rats Is Dose-Dependent and Mediated by BKCa Channels. J Cardiovasc Pharmacol. 2017;69(4):228–35. https://doi.org/10.1097/fjc.0000000000000466 .

doi: 10.1097/fjc.0000000000000466 pubmed: 28375904

Raupach A, Karakurt E, Torregroza C, et al. Dexmedetomidine provides cardioprotection during early or late reperfusion mediated by different mitochondrial K+-channels. Anesth Analg. 2021;132(1):253–60. https://doi.org/10.1213/ane.0000000000005148 .

doi: 10.1213/ane.0000000000005148 pubmed: 32889843

Du J, Xu Z, Zhen J et al. Dexmedetomidine attenuates myocardial ischemia/reperfusion injury through regulating lactate signaling cascade in mice. Eur Rev Med Pharmacol Sci. 2019;23(8):3527-32. https://doi.org/10.26355/eurrev_201904_17721 .

She H, Zhu Y, Deng H, et al. Protective Effects of Dexmedetomidine on the Vascular Endothelial Barrier Function by Inhibiting Mitochondrial Fission via ER/Mitochondria Contact. Front Cell Develop Biol. 2021;9: 636327. https://doi.org/10.3389/fcell.2021.636327 .

doi: 10.3389/fcell.2021.636327

Sun YJ, Jiang C, Jiang J, Qiu LS. Dexmedetomidine protects mice against myocardium ischaemic/reperfusion injury by activating an AMPK/PI3K/Akt/eNOS pathway. Clin Exp Pharmacol Physiol. 2017;44(9):946–53. https://doi.org/10.1111/1440-1681.12791 .

doi: 10.1111/1440-1681.12791 pubmed: 28556946

Riquelme JA, Westermeier F, Hall AR, et al. Dexmedetomidine protects the heart against ischemia-reperfusion injury by an endothelial eNOS/NO dependent mechanism. Pharmacol Res. 2016;103:318–27. https://doi.org/10.1016/j.phrs.2015.11.004 .

doi: 10.1016/j.phrs.2015.11.004 pubmed: 26607864

He L, Hao SQ, Wang YQ et al. Dexmedetomidine preconditioning attenuates ischemia/reperfusion injury in isolated rat hearts with endothelial dysfunction. Biomed Pharmacother. 2019;114:108837. https://doi.org/10.1016/j.biopha.2019.108837 .

Tang X, Zhang C, Tian T, et al. Posttreatment with dexmedetomidine aggravates LPS-induced myocardial dysfunction partly via activating cardiac endothelial α(2A)-AR in mice. Int Immunopharmacol. 2023;116:109724. https://doi.org/10.1016/j.intimp.2023.109724 .

doi: 10.1016/j.intimp.2023.109724 pubmed: 36696856

Yoshikawa Y, Hirata N, Kawaguchi R, Tokinaga Y, Yamakage M. Dexmedetomidine maintains its direct cardioprotective effect against ischemia/reperfusion injury in hypertensive hypertrophied myocardium. Anesth Analg. 2018;126(2):443–52. https://doi.org/10.1213/ANE.0000000000002452 .

doi: 10.1213/ANE.0000000000002452 pubmed: 28914648

Maltsev AV, Evdokimovskii EV, Kokoz YM. α2-Adrenoceptor signaling in cardiomyocytes of spontaneously hypertensive rats starts to impair already at early age. Biochem Biophys Research Commun. 2019;512(4):908–13. https://doi.org/10.1016/j.bbrc.2019.03.117 .

doi: 10.1016/j.bbrc.2019.03.117

Chai YF, Yu RY, Liu Y et al. Dexmedetomidine attenuates monocyte-endothelial adherence via inhibiting connexin43 on vascular endothelial cells. Mediators Inflamm. 2020;2020:7039854-. https://doi.org/10.1155/2020/7039854 .

Miranda ML, Balarini MM, Bouskela E. Dexmedetomidine attenuates the microcirculatory derangements evoked by experimental sepsis. Anesthesiology. 2015;122(3):619–30. https://doi.org/10.1097/ALN.0000000000000491 .

doi: 10.1097/ALN.0000000000000491 pubmed: 25313879

Arslan M, Comu FM, Kip G, et al. Effect of dexmedetomidine on erythrocyte deformability during ischaemia-reperfusion injury of heart in diabetic rats. Bratisl Lek Listy. 2014;115(8):494–7. https://doi.org/10.4149/bll_2014_096 .

doi: 10.4149/bll_2014_096 pubmed: 25246286

Han H, Dai DP, Hu JQ, et al. Dexmedetomidine improves cardiac function and protects against maladaptive remodeling following myocardial infarction. Mol Med Rep. 2019;20(6):5183–9. https://doi.org/10.3892/mmr.2019.10774 .

doi: 10.3892/mmr.2019.10774 pubmed: 31661145 pmcid: 6854534

Wu SJ, Lin ZH, Lin YZ, et al. Dexmedetomidine exerted anti-arrhythmic effects in rat with ischemic cardiomyopathy via upregulation of connexin 43 and reduction of fibrosis and inflammation. Front Physiol. 2020;11:33-. https://doi.org/10.3389/fphys.2020.00033 .

Liao J, Li K, Su X, et al. Dexmedetomidine promotes lipopolysaccharide-induced differentiation of cardiac fibroblasts and collagen I/III synthesis through α(2A) adrenoreceptor-mediated activation of the PKC-p38-Smad2/3 signaling pathway in mice. Int J Mol Sci. 2021;22(23). https://doi.org/10.3390/ijms222312749 .

Siebert V, Allencherril J, Ye Y, Wehrens XHT, Birnbaum Y. The role of non-coding RNAs in ischemic myocardial reperfusion injury. Cardiovasc Drugs Ther. 2019;33(4):489–98. https://doi.org/10.1007/s10557-019-06893-x .

doi: 10.1007/s10557-019-06893-x pubmed: 31332654

Wang LY, Tang SM, Wang ZR et al. The administration of dexmedetomidine changes microRNA expression profiling of rat hearts. Biomed Pharmacother. 2019;120:109463-. https://doi.org/10.1016/j.biopha.2019.109463 .

Yang XH, Chen HM, Chen Y, et al. Circulating miRNA expression profiling and target prediction in patients receiving dexmedetomidine. Cell Physiol Biochem. 2018;50(2):552–68. https://doi.org/10.1159/000494168 .

doi: 10.1159/000494168 pubmed: 30308506

Cai X, Li B, Wei W, et al. Circulating microRNA-30a-5p, microRNA-101-3p, microRNA-140-3p and microRNA-141-3p as potential biomarkers for dexmedetomidine response in pediatric patients. Eur J Clin Pharmacol. 2021;77(12):1853–9. https://doi.org/10.1007/s00228-021-03178-x .

doi: 10.1007/s00228-021-03178-x pubmed: 34216249

Yoshikawa Y, Hirata N, Terada H, Sawashita Y, Yamakage M. Identification of candidate genes and pathways in dexmedetomidine-induced cardioprotection in the rat heart by bioinformatics analysis. Int J Mol Sci. 2019;20(7):1614. https://doi.org/10.3390/ijms20071614 .

doi: 10.3390/ijms20071614 pubmed: 30939728 pmcid: 6480577

Wang Z, Yang Y, Xiong W, et al. Dexmedetomidine protects H9C2 against hypoxia/reoxygenation injury through miR-208b-3p/Med13/Wnt signaling pathway axis. Biomed Pharmacother. 2020;125: 110001. https://doi.org/10.1016/j.biopha.2020.110001 .

doi: 10.1016/j.biopha.2020.110001 pubmed: 32070878

Guo P, Yi H, Han M, et al. Dexmedetomidine alleviates myocardial ischemia-reperfusion injury by down-regulating miR-34b-3p to activate the Jagged1/Notch signaling pathway. Int Immunopharmacol. 2023;116: 109766. https://doi.org/10.1016/j.intimp.2023.109766 .

doi: 10.1016/j.intimp.2023.109766 pubmed: 36764271

Yu J, Yang W, Wang W et al. Involvement of miR-665 in protection effect of dexmedetomidine against Oxidative Stress Injury in myocardial cells via CB2 and CK1. Biomed Pharmacother. 2019;115:108894-. https://doi.org/10.1016/j.biopha.2019.108894 .

He L, Wang Z, Zhou R, et al. Dexmedetomidine exerts cardioprotective effect through miR-146a-3p targeting IRAK1 and TRAF6 via inhibition of the NF-κB pathway. Biomed Pharmacother. 2021;133: 110993. https://doi.org/10.1016/j.biopha.2020.110993 .

doi: 10.1016/j.biopha.2020.110993 pubmed: 33220608

Liu C, Xu R. Dexmedetomidine protects H9C2 rat cardiomyocytes against hypoxia/reoxygenation injury by regulating the long non-coding RNA colon cancer-associated transcript 1/microRNA-8063/Wnt/β-catenin axis. Bioengineered. 2022;13(5):13300–11. https://doi.org/10.1080/21655979.2022.2080420 .

doi: 10.1080/21655979.2022.2080420 pubmed: 35635079 pmcid: 9275899

Chang Y, Xing L, Zhou W, Zhang W. Up-regulating microRNA-138-5p enhances the protective role of dexmedetomidine on myocardial ischemia-reperfusion injury mice via down-regulating Ltb4r1. Cell cycle (Georgetown, Tex). 2021;20(4):445–58. https://doi.org/10.1080/15384101.2021.1878330 .

doi: 10.1080/15384101.2021.1878330 pubmed: 33509010 pmcid: 7894414

Deng Y, Cai L, Wang F, et al. Upregulated microRNA-381-5p strengthens the effect of dexmedetomidine preconditioning to protect against myocardial ischemia-reperfusion injury in mouse models by inhibiting CHI3L1. Int Immunopharmacol. 2021;92: 107326. https://doi.org/10.1016/j.intimp.2020.107326 .

doi: 10.1016/j.intimp.2020.107326 pubmed: 33461162

Laggerbauer B, Engelhardt S. MicroRNAs as therapeutic targets in cardiovascular disease. The Journal of clinical investigation. 2022;132(11). https://doi.org/10.1172/jci159179 .

Silpa AR, Koshy KA, Subramanian A, Pradeep KK. Comparison of the efficacy of two doses of dexmedetomidine in attenuating the hemodynamic response to intubation in patients undergoing elective cardiac surgery: A randomized double-blinded study. J Anaesthesiol Clin Pharmacol. 2020;36(1):83–7. https://doi.org/10.4103/joacp.JOACP_235_18 .

doi: 10.4103/joacp.JOACP_235_18 pubmed: 32174664 pmcid: 7047691

Tan C, Yan S, Shen J, et al. Effects of dexmedetomidine on cardiac electrophysiology in patients undergoing general anesthesia during perioperative period: a randomized controlled trial. BMC Anesthesiol. 2022;22(1):271. https://doi.org/10.1186/s12871-022-01811-5 .

doi: 10.1186/s12871-022-01811-5 pubmed: 36008759 pmcid: 9404616

Ellermann C, Brandt J, Wolfes J, et al. Safe electrophysiologic profile of dexmedetomidine in different experimental arrhythmia models. Scientific reports. 2021;11(1):23940. https://doi.org/10.1038/s41598-021-03364-y .

doi: 10.1038/s41598-021-03364-y pubmed: 34907251 pmcid: 8671395

Deng L, Chen H, Wei N, Zhang ZD, Wang GN. The cardioprotective effect of dexmedetomidine on regional ischemia/reperfusion injury in type 2 diabetic rat hearts. Microvasc Res. 2019;123:1–6. https://doi.org/10.1016/j.mvr.2018.08.006 .

doi: 10.1016/j.mvr.2018.08.006 pubmed: 30179598

Gautam NK, Turiy Y, Srinivasan C. Preincision initiation of dexmedetomidine maximally reduces the risk of junctional ectopic tachycardia in children undergoing ventricular septal defect repairs. J Cardiothorac Vasc Anesth. 2017;31(6):1960–5. https://doi.org/10.1053/j.jvca.2017.04.010 .

doi: 10.1053/j.jvca.2017.04.010 pubmed: 28774644

Shuplock JM, Smith AH, Owen J, et al. Association between perioperative dexmedetomidine and arrhythmias after surgery for congenital heart disease. Circ Arrhythm Electrophysiol. 2015;8(3):643–50. https://doi.org/10.1161/CIRCEP.114.002301 .

doi: 10.1161/CIRCEP.114.002301 pubmed: 25878324 pmcid: 4472529

Ueno K, Ninomiya Y, Shiokawa N, et al. Dexmedetomidine is associated with an increased incidence of bradycardia in patients with trisomy 21 after surgery for congenital heart disease. Pediatr Cardiol. 2016;37(7):1228–34. https://doi.org/10.1007/s00246-016-1421-8 .

doi: 10.1007/s00246-016-1421-8 pubmed: 27272693

Turan A, Duncan A, Leung S, et al. Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial. Lancet (London, England). 2020;396(10245):177–85. https://doi.org/10.1016/s0140-6736(20)30631-0 .

doi: 10.1016/s0140-6736(20)30631-0 pubmed: 32682483

Goins AE, Rayson R, Caughey MC, et al. Correlation of infarct size with invasive hemodynamics in patients with ST-elevation myocardial infarction. Catheter Cardiovasc Intervent. 2018;92(5):E333-e40. https://doi.org/10.1002/ccd.27625 .

doi: 10.1002/ccd.27625

Wang K, Wu M, Xu J, et al. Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: systematic review and meta-analysis. Br J Anaesth. 2019;123(6):777–94. https://doi.org/10.1016/j.bja.2019.07.027 .

doi: 10.1016/j.bja.2019.07.027 pubmed: 31668347

Wang D, Lin Q, Du M et al. Protective effect of dexmedetomidine on perioperative myocardial injury in patients with Stanford type-A aortic dissection. Revista da Associacao Medica Brasileira (1992). 2020;66(12):1638-44. https://doi.org/10.1590/1806-9282.66.12.1638 .

Cui J, Gao M, Huang H, Huang X, Zeng Q. Dexmedetomidine improves lung function by promoting inflammation resolution in patients undergoing totally thoracoscopic cardiac surgery. Oxid Med Cell Longev. 2020;2020:8638301. https://doi.org/10.1155/2020/8638301 .

doi: 10.1155/2020/8638301 pubmed: 32963704 pmcid: 7495214

Wu H, Tang J, Pan J, et al. Effects of dexmedetomidine on stress hormones in patients undergoing cardiac valve replacement: a randomized controlled trial. BMC Anesthesiol. 2020;20(1):142. https://doi.org/10.1186/s12871-020-00993-0 .

doi: 10.1186/s12871-020-00993-0 pubmed: 32505177 pmcid: 7275125

Zakkar M, Ascione R, James AF, Angelini GD, Suleiman MS. Inflammation, oxidative stress and postoperative atrial fibrillation in cardiac surgery. Pharmacol Ther. 2015;154:13–20. https://doi.org/10.1016/j.pharmthera.2015.06.009 .

doi: 10.1016/j.pharmthera.2015.06.009 pubmed: 26116810

Pang Y, Li Y, Zhang Y, et al. Effects of inflammation and oxidative stress on postoperative delirium in cardiac surgery. Front Cardiovasc Med. 2022;9:1049600. https://doi.org/10.3389/fcvm.2022.1049600 .

doi: 10.3389/fcvm.2022.1049600 pubmed: 36505383 pmcid: 9731159

Li AW, Yuen VMY, Goulay-Dufay S, Kwok PCL. Pharmacokinetics and pharmacodynamics of dexmedetomidine. Drug Dev Ind Pharm. 2016;42(12):1917–27. https://doi.org/10.1080/03639045.2016.1232727 .

doi: 10.1080/03639045.2016.1232727 pubmed: 27595299

Choi YJ, Park KH, Park JY, Min WK, Lee YS. The effect of alpha-2A adrenergic receptor (ADRA2A) genetic polymorphisms on the depth of sedation of dexmedetomidine: a genetic observational pilot study. Brazil J Anesthesiol. 2022;72(2):241–6. https://doi.org/10.1016/j.bjane.2021.04.005 .

doi: 10.1016/j.bjane.2021.04.005

Yağar S, Yavaş S, Karahalil B. The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery. Mol Biol Rep. 2011;38(5):3383–9. https://doi.org/10.1007/s11033-010-0446-y .

doi: 10.1007/s11033-010-0446-y pubmed: 21104443

Zhu SJ, Wang KR, Zhang XX, Zhu SM. Relationship between genetic variation in the α(2A)-adrenergic receptor and the cardiovascular effects of dexmedetomidine in the Chinese Han population. J Zhejiang Univ Sci B. 2019;20(7):598–604. https://doi.org/10.1631/jzus.B1800647 .

doi: 10.1631/jzus.B1800647 pubmed: 31168973 pmcid: 6586997

Friesen RH, Slavov D, Miyamoto SD, et al. Lack of association between adrenoreceptor genotype and the vasoconstriction response to dexmedetomidine. Semin Cardiothorac Vasc Anesth. 2017;21(4):341–4. https://doi.org/10.1177/1089253217708621 .

doi: 10.1177/1089253217708621 pubmed: 28482761

Gallaway KA, Skaar TC, Biju A, Slaven J, Tillman EM. A pilot study of ADRA2A genotype association with doses of dexmedetomidine for sedation in pediatric patients. Pharmacotherapy. 2022;42(6):453–9. https://doi.org/10.1002/phar.2684 .

doi: 10.1002/phar.2684 pubmed: 35429176 pmcid: 9325491

Fang C, Ouyang W, Zeng Y, et al. CYP2A6 and GABRA2 gene polymorphisms are associated with dexmedetomidine drug response. Front Pharmacol. 2022;13:943200. https://doi.org/10.3389/fphar.2022.943200 .

doi: 10.3389/fphar.2022.943200 pubmed: 35873555 pmcid: 9301121

Ling Y, Gao H, Wang J, et al. Effects of dexmedetomidine and ACE genotype on cardiovascular response during the decannulation period of general anesthesia in patients with essential hypertension. Clin Ther. 2020;42(10):1992–2000. https://doi.org/10.1016/j.clinthera.2020.07.012 .

doi: 10.1016/j.clinthera.2020.07.012 pubmed: 32839029

Li YY, Ge DJ, Li JY, Qi B. Sex differences in the morphine-sparing effects of intraoperative dexmedetomidine in patient-controlled analgesia following general anesthesia: a consort-prospective, randomized, controlled clinical trial. Medicine. 2016;95(18): e3619. https://doi.org/10.1097/md.0000000000003619 .

doi: 10.1097/md.0000000000003619 pubmed: 27149500 pmcid: 4863817

Holliday SF, Kane-Gill SL, Empey PE, Buckley MS, Smithburger PL. Interpatient variability in dexmedetomidine response: a survey of the literature. Sci World J. 2014;2014: 805013. https://doi.org/10.1155/2014/805013 .

doi: 10.1155/2014/805013

Davy A, Fessler J, Fischler M, Le Guen M. Dexmedetomidine and general anesthesia: a narrative literature review of its major indications for use in adults undergoing non-cardiac surgery. Minerva Anestesiol. 2017;83(12):1294-308. https://doi.org/10.23736/S0375-9393.17.12040-7 .

Insight into Cardioprotective Effects and Mechanisms of Dexmedetomidine.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Subventions

Informations de copyright

Références

Auteurs

Leyu Jiang (L)

Wei Xiong (W)

Yuqiao Yang (Y)

Jinqiao Qian (J)

Classifications MeSH